FDA Accepts Replimune's Melanoma Drug Resubmission, Sets August 2 Decision Date
REPL has more than doubled off its 52-week low of $1.5 on light trading volume (0.3× avg).
Summary
The FDA has accepted Replimune's resubmission of its Biologics License Application for RP1 in advanced melanoma. This follows the FDA's previous Complete Response Letter in April and the company's subsequent agreement to resubmit in late May. The acceptance is a crucial step towards potential approval for RP1, the company's lead product. The FDA has set an action date of August 2, 2026, with an advisory committee meeting anticipated in late July. These dates provide clear milestones for the market.
At the time of this announcement, REPL was trading at $11.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $919M. The 52-week trading range was $1.50 to $13.24. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.